AstraZeneca (NYSE:AZN) released its quarterly earnings data on Thursday. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04, MarketWatch Earnings reports. AstraZeneca had a net margin of 8.36% and a return on equity of 37.83%. The business had revenue of $6.28 billion during the quarter, compared to analyst estimates of $6.27 billion. During the same period in the previous year, the business earned $0.73 EPS. AstraZeneca’s revenue was up 9.7% compared to the same quarter last year.

Shares of AstraZeneca stock traded down $2.11 during trading on Friday, reaching $55.78. 6,844,544 shares of the stock were exchanged, compared to its average volume of 10,823,646. AstraZeneca has a 1 year low of $36.15 and a 1 year high of $64.94. The firm has a market cap of $146.39 billion, a price-to-earnings ratio of 67.20, a price-to-earnings-growth ratio of 1.71 and a beta of 0.55. The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 1.32. The stock’s fifty day moving average is $54.53 and its 200 day moving average is $50.30.

The company also recently disclosed a semi-annual dividend, which will be paid on Monday, September 14th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.45 per share. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th. AstraZeneca’s dividend payout ratio (DPR) is 106.29%.

Several research analysts have commented on AZN shares. Barclays restated an “overweight” rating on shares of AstraZeneca in a research note on Wednesday. Cowen boosted their price target on shares of AstraZeneca from $55.00 to $60.00 in a research report on Wednesday, June 10th. Oddo Bhf lowered AstraZeneca from a “buy” rating to a “reduce” rating in a report on Wednesday, June 24th. SVB Leerink increased their target price on AstraZeneca from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. Finally, Zacks Investment Research cut shares of AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 price target on the stock. in a research report on Wednesday. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $61.00.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Cash Flow

Earnings History for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.